A personalized dendritic cell vaccine using tumor-specific neoantigen peptides achieved a 25% response rate and 75% disease control rate in heavily pretreated advanced lung cancer patients with only mild side effects.
75% disease controlThree-quarters of heavily pretreated advanced lung cancer patients achieved disease control with personalized neoantigen DC vaccine
What the researchers found
In 12 advanced lung cancer patients, personalized neoantigen DC vaccine achieved 25% objective response rate, 75% disease control rate, 5.5-month median progression-free survival, and 7.9-month median overall survival with only grade 1-2 adverse events.
Why it matters
Lung cancer is the deadliest cancer worldwide, and many patients exhaust standard treatment options. Personalized neoantigen vaccines represent a fundamentally different approach that trains the immune system to specifically target each patient's unique tumor.
The numbers in context
12 patients; 85 vaccine treatments; median 5 doses/person; 12-30 neoantigens/patient; ORR 25%; DCR 75%; mPFS 5.5 months; mOS 7.9 months; all AEs grade 1-2
How the study worked
Single-arm, 2-center pilot study. Whole-exome and RNA sequencing of tumor biopsies identified candidate neoantigens. 12-30 neoantigen peptides per patient were used to pulse autologous dendritic cells. 85 total vaccine treatments administered (median 5 doses/person, range 3-14).
Who was studied
Heavily treated metastatic lung cancer patients
What this study cannot tell us
Very small sample size (12 patients). Single-arm design without a control group. All patients were heavily pretreated, making it difficult to compare outcomes. Neoantigen identification and vaccine production are complex and time-consuming. Requires fresh tumor biopsy material.
How to read the evidence
Low-to-moderate evidence: pilot study with only 12 patients and no control group, but uses rigorous genomic-guided personalization and demonstrates a clear clinical signal.
When this study was published
Published in 2021. Neoantigen vaccine research has accelerated significantly with multiple larger clinical trials now underway.
The bigger picture
Neoantigen vaccines are a frontier of personalized cancer immunotherapy. This pilot study adds to growing evidence that peptide-based vaccines can benefit even heavily pretreated cancer patients, potentially complementing checkpoint inhibitors and other immunotherapies.
Questions still open
- Would combining neoantigen vaccines with checkpoint inhibitors improve response rates?
- Can the vaccine manufacturing process be streamlined for broader clinical use?
- Would earlier use of neoantigen vaccines (before heavy pretreatment) produce better outcomes?
Common questions
What is a neoantigen vaccine?
Is this treatment available to lung cancer patients now?
Read the original research
Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer.
Signal transduction and targeted therapy, 6(1), 26
Citation
Ding, Zhenyu; Li, Qing; Zhang, Rui; Xie, Li; Shu, Yang; Gao, Song; Wang, Peipei; Su, Xiaoqing; Qin, Yun; Wang, Yuelan; Fang, Juemin; Zhu, Zhongzheng; Xia, Xuyang; Wei, Guochao; Wang, Hui; Qian, Hong; Guo, Xianling; Gao, Zhibo; Wang, Yu; Wei, Yuquan; Xu, Qing; Xu, Heng; Yang, Li. (2021). Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer.. Signal transduction and targeted therapy, 6(1), 26. https://doi.org/10.1038/s41392-020-00448-5